United Therapeutics (NASDAQ:UTHR) CEO Sells $5,362,845.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $564.51, for a total transaction of $5,362,845.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $183,151,317.93. This represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Trading Up 1.2%

Shares of NASDAQ UTHR opened at $595.66 on Thursday. United Therapeutics Corporation has a 1-year low of $452.44 and a 1-year high of $614.23. The company has a market cap of $25.37 billion, a PE ratio of 22.48, a P/E/G ratio of 3.94 and a beta of 0.49. The company has a 50-day moving average of $538.56 and a two-hundred day moving average of $535.20.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The company had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. During the same quarter in the previous year, the company posted $7.16 earnings per share. United Therapeutics’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.90 earnings per share for the current year.

United Therapeutics declared that its board has initiated a stock repurchase program on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 8.3% of its stock through open market purchases. Share buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Latest United Therapeutics News

These are some of the UTHR news items that stood out recently:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, above the share price cited in the background. Its forecasts call for EPS to rise from $27.46 in FY2026 to $53.67 in FY2030, signaling confidence in longer-term earnings growth. HC Wainwright coverage report
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares on November 6 and another 9,500 shares across transactions on November 9. Director Christopher Patusky also sold 1,210 shares, reducing his position by 36.12%. Insider selling can weigh on sentiment, although both executives retain shares. SEC filing

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group set a $725.00 target price on United Therapeutics in a research report on Monday, October 19th. BTIG Research raised their price target on United Therapeutics from $728.00 to $768.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 14th. Weiss Ratings cut United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, Morgan Stanley boosted their price objective on United Therapeutics from $515.00 to $566.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $676.40.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Advisors Asset Management Inc. bought a new stake in United Therapeutics in the third quarter valued at about $23,850,000. Edmond DE Rothschild Holding S.A. boosted its holdings in United Therapeutics by 245.8% during the third quarter. Edmond DE Rothschild Holding S.A. now owns 2,932 shares of the biotechnology company’s stock worth $1,589,000 after buying an additional 2,084 shares during the last quarter. Private Wealth Asset Management LLC acquired a new position in shares of United Therapeutics during the 3rd quarter worth about $276,000. Private Advisor Group LLC grew its position in shares of United Therapeutics by 24.6% during the 3rd quarter. Private Advisor Group LLC now owns 1,730 shares of the biotechnology company’s stock worth $938,000 after buying an additional 342 shares during the period. Finally, Focus Advisor Solutions LLC grew its position in shares of United Therapeutics by 46.6% during the 3rd quarter. Focus Advisor Solutions LLC now owns 2,151 shares of the biotechnology company’s stock worth $1,166,000 after buying an additional 684 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.